- Home
- QGEN vs COO Comparison
QGEN vs COO Comparison
Compare QGEN & COO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QGEN | COO |
|---|---|---|
| Founded | 1986 | 1980 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Ophthalmic Goods |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2B | 11.6B |
| IPO Year | 1998 | 1994 |
Fundamental Metrics
Financial Performance| Metric | QGEN | COO |
|---|---|---|
| Price | $33.05 | $59.75 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 11 |
| Target Price | $45.76 | ★ $90.18 |
| AVG Volume (30 Days) | ★ 2.2M | 2.1M |
| Earning Date | 05-06-2026 | 05-28-2026 |
| Dividend Yield | ★ 7.17% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.66 |
| Revenue | N/A | ★ $2,532,800,000.00 |
| Revenue This Year | $8.18 | $6.66 |
| Revenue Next Year | $5.71 | $5.18 |
| P/E Ratio | ★ $24.01 | $91.47 |
| Revenue Growth | N/A | ★ 18.41 |
| 52 Week Low | $32.53 | $58.89 |
| 52 Week High | $57.82 | $89.83 |
Technical Indicators
Market Signals| Indicator | QGEN | COO |
|---|---|---|
| Relative Strength Index (RSI) | 32.56 | 29.44 |
| Support Level | N/A | N/A |
| Resistance Level | $49.16 | $70.01 |
| Average True Range (ATR) | 0.88 | 1.60 |
| MACD | 0.04 | 0.09 |
| Stochastic Oscillator | 18.36 | 12.81 |
Price Performance
Historical ComparisonAbout QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
About COO The Cooper Companies Inc.
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.